| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Yu Kang | Q51301642 |
| P2093 | author name string | Hua Wang | |
| Lu Chen | |||
| Su Zeng | |||
| Lushan Yu | |||
| Junqing Liu | |||
| Jiabei Zhou | |||
| P2860 | cites work | Human copper transporter 2 is localized in late endosomes and lysosomes and facilitates cellular copper uptake | Q24654300 |
| Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer | Q26747806 | ||
| Loss of Scribble confers cisplatin resistance during NSCLC chemotherapy via Nox2/ROS and Nrf2/PD-L1 signaling | Q93179119 | ||
| Omeprazole protects against cisplatin-induced nephrotoxicity by alleviating oxidative stress, inflammation, and transporter-mediated cisplatin accumulation in rats and HK-2 cells | Q93212716 | ||
| Therapy resistance mediated by cancer stem cells | Q93339813 | ||
| The Functions of Metallothionein and ZIP and ZnT Transporters: An Overview and Perspective | Q26766916 | ||
| Resistance and gain-of-resistance phenotypes in cancers harboring wild-type p53 | Q27006998 | ||
| In vivo activation of the p53 pathway by small-molecule antagonists of MDM2 | Q27642888 | ||
| Crystal Structures of Cisplatin Bound to a Human Copper Chaperone | Q27657700 | ||
| A common polymorphism in the 5' UTR of ERCC5 creates an upstream ORF that confers resistance to platinum-based chemotherapy | Q27853206 | ||
| An African-specific polymorphism in the TP53 gene impairs p53 tumor suppressor function in a mouse model | Q27853369 | ||
| The status of platinum anticancer drugs in the clinic and in clinical trials | Q28286605 | ||
| A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with decreased drug accumulation | Q28289092 | ||
| Glutathione in cancer biology and therapy | Q28300422 | ||
| Endoplasmic reticulum stress is involved in the response of human laryngeal carcinoma cells to Carboplatin but is absent in Carboplatin-resistant cells | Q28533746 | ||
| Multidrug Resistance-Associated Protein 2 (MRP2) Mediated Transport of Oxaliplatin-Derived Platinum in Membrane Vesicles | Q28546068 | ||
| Dihydromyricetin Enhances the Chemo-Sensitivity of Nedaplatin via Regulation of the p53/Bcl-2 Pathway in Hepatocellular Carcinoma Cells | Q28546762 | ||
| The Essential Role of H19 Contributing to Cisplatin Resistance by Regulating Glutathione Metabolism in High-Grade Serous Ovarian Cancer | Q28833833 | ||
| Functional activation of mutant p53V172F by platinum analogs in cisplatin-resistant human tumor cells is dependent on serine-20 phosphorylation | Q29248201 | ||
| The mutational landscape of head and neck squamous cell carcinoma | Q29614654 | ||
| Modes of p53 regulation | Q29615657 | ||
| Transcriptional control of human p53-regulated genes | Q29617650 | ||
| The impact of O2 availability on human cancer | Q29619884 | ||
| Hypoxia-inducible factor-1 alpha, in association with inflammation, angiogenesis and MYC, is a critical prognostic factor in patients with HCC after surgery | Q30932207 | ||
| Up-regulation of miR-146a increases the sensitivity of non-small cell lung cancer to DDP by downregulating cyclin J. | Q32182056 | ||
| Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. | Q33209208 | ||
| Altered localisation of the copper efflux transporters ATP7A and ATP7B associated with cisplatin resistance in human ovarian carcinoma cells. | Q33345021 | ||
| A phase 2 study of nanoparticle albumin-bound paclitaxel plus nedaplatin for patients with advanced, recurrent, or metastatic cervical carcinoma | Q33435722 | ||
| Multi-institutional prospective study of nedaplatin plus S-1 chemotherapy in recurrent and metastatic nasopharyngeal carcinoma patients after failure of platinum-containing regimens | Q33439361 | ||
| Comparative adverse effect profiles of platinum drugs. | Q33495298 | ||
| Differential transport of platinum compounds by the human organic cation transporter hOCT2 (hSLC22A2). | Q33523365 | ||
| Exosomal transfer of tumor-associated macrophage-derived miR-21 confers cisplatin resistance in gastric cancer cells | Q33560646 | ||
| Wwox-Brca1 interaction: role in DNA repair pathway choice | Q33585936 | ||
| Hypoxia-inducible factor 1alpha determines gastric cancer chemosensitivity via modulation of p53 and NF-kappaB | Q33656653 | ||
| USP13 regulates the RAP80-BRCA1 complex dependent DNA damage response | Q33770883 | ||
| Copper transporter 2 regulates the cellular accumulation and cytotoxicity of Cisplatin and Carboplatin | Q33822719 | ||
| Copper transporter CTR1 expression and tissue platinum concentration in non-small cell lung cancer | Q33875938 | ||
| Platinum anticancer drug damage enforces a particular rotational setting of DNA in nucleosomes | Q33934039 | ||
| Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas. | Q33944203 | ||
| Enhancing tumor-specific uptake of the anticancer drug cisplatin with a copper chelator | Q33986172 | ||
| Association between the level of ERCC-1 expression and the repair of cisplatin-induced DNA damage in human ovarian cancer cells. | Q52168383 | ||
| Targeting the microenvironment in solid tumors. | Q52368266 | ||
| Autocrine activation of JAK2 by IL-11 promotes platinum drug resistance. | Q52584568 | ||
| MiR-216b increases cisplatin sensitivity in ovarian cancer cells by targeting PARP1. | Q52679638 | ||
| Multidrug resistance proteins (MRPs, ABCCs): importance for pathophysiology and drug therapy | Q37811966 | ||
| DNA damage-induced cell death: from specific DNA lesions to the DNA damage response and apoptosis | Q37977244 | ||
| Prostate cancer, miRNAs, metallothioneins and resistance to cytostatic drugs. | Q38060257 | ||
| In brief: BRCA1 and BRCA2. | Q38101887 | ||
| Targeting apoptosis pathways for new cancer therapeutics. | Q38159798 | ||
| Increased levels and defective glycosylation of MRPs in ovarian carcinoma cells resistant to oxaliplatin. | Q38348095 | ||
| Targeting autophagy to overcome drug resistance in cancer therapy | Q38579547 | ||
| Hypoxia-inducible factor 3 biology: complexities and emerging themes | Q38631669 | ||
| Lung cancer stem cells: The root of resistance | Q38706873 | ||
| A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress | Q38713515 | ||
| PGRMC1-dependent autophagy by hyperoside induces apoptosis and sensitizes ovarian cancer cells to cisplatin treatment | Q38716461 | ||
| Resveratrol-induced autophagy and apoptosis in cisplatin-resistant human oral cancer CAR cells: A key role of AMPK and Akt/mTOR signaling | Q38716472 | ||
| XPF knockout via CRISPR/Cas9 reveals that ERCC1 is retained in the cytoplasm without its heterodimer partner XPF. | Q38719028 | ||
| The role of Nrf2 and ATF2 in resistance to platinum-based chemotherapy | Q38719571 | ||
| ABCF2, an Nrf2 target gene, contributes to cisplatin resistance in ovarian cancer cells | Q38719990 | ||
| miR-148a increases the sensitivity to cisplatin by targeting Rab14 in renal cancer cells | Q38720776 | ||
| The FA/BRCA Pathway Identified as the Major Predictor of Cisplatin Response in Head and Neck Cancer by Functional Genomics | Q38726035 | ||
| HIF-1 in cancer therapy: two decade long story of a transcription factor. | Q38737693 | ||
| Lobaplatin induces BGC-823 human gastric carcinoma cell apoptosis via ROS- mitochondrial apoptotic pathway and impairs cell migration and invasion | Q38738592 | ||
| Long non-coding RNA UCA1 promotes cisplatin/gemcitabine resistance through CREB modulating miR-196a-5p in bladder cancer cells | Q38739426 | ||
| Higher expression of XPF is a critical factor in intrinsic chemotherapy resistance of human renal cell carcinoma | Q38750997 | ||
| miR-374a-CCND1-pPI3K/AKT-c-JUN feedback loop modulated by PDCD4 suppresses cell growth, metastasis, and sensitizes nasopharyngeal carcinoma to cisplatin | Q38766169 | ||
| miR-133a enhances the sensitivity of Hep-2 cells and vincristine-resistant Hep-2v cells to cisplatin by downregulating ATP7B expression | Q38775007 | ||
| Cisplatin-induced CCL5 secretion from CAFs promotes cisplatin-resistance in ovarian cancer via regulation of the STAT3 and PI3K/Akt signaling pathways | Q38785774 | ||
| Long non-coding RNA AC023115.3 suppresses chemoresistance of glioblastoma by reducing autophagy | Q38788700 | ||
| miR-409-3p sensitizes colon cancer cells to oxaliplatin by inhibiting Beclin-1-mediated autophagy | Q38789468 | ||
| Enhancement of Drug Sensitivity by Knockdown of HIF-1α in Gastric Carcinoma Cells | Q38789826 | ||
| miR-17-92 plays an oncogenic role and conveys chemo-resistance to cisplatin in human prostate cancer cells | Q38792994 | ||
| NF-κB signaling plays irreplaceable roles in cisplatin-induced bladder cancer chemoresistance and tumor progression | Q38813417 | ||
| Autophagic flux promotes cisplatin resistance in human ovarian carcinoma cells through ATP-mediated lysosomal function. | Q38833368 | ||
| MiR-873 acts as a novel sensitizer of glioma cells to cisplatin by targeting Bcl-2. | Q38839310 | ||
| Catechols and 3-hydroxypyridones as inhibitors of the DNA repair complex ERCC1-XPF. | Q38839750 | ||
| miR-634 Activates the Mitochondrial Apoptosis Pathway and Enhances Chemotherapy-Induced Cytotoxicity | Q38848758 | ||
| Recent advance in the pharmacogenomics of human Solute Carrier Transporters (SLCs) in drug disposition. | Q38870052 | ||
| Autophagy regulates cisplatin-induced stemness and chemoresistance via the upregulation of CD44, ABCB1 and ADAM17 in oral squamous cell carcinoma | Q47368849 | ||
| MicroRNA-195 acts as an anti-proliferative miRNA in human melanoma cells by targeting Prohibitin 1. | Q47616712 | ||
| MiR-5100 increases the cisplatin resistance of the lung cancer stem cells by inhibiting the Rab6. | Q47709751 | ||
| MicroRNA-148a-3p enhances cisplatin cytotoxicity in gastric cancer through mitochondrial fission induction and cyto-protective autophagy suppression | Q47719136 | ||
| MRP4/ABCC4 as a new therapeutic target: meta-analysis to determine cAMP binding sites as a tool for drug design. | Q47760720 | ||
| Mxd1 mediates hypoxia-induced cisplatin resistance in osteosarcoma cells by repression of the PTEN tumor suppressor gene. | Q47881043 | ||
| RAD6 promotes DNA repair and stem cell signaling in ovarian cancer and is a promising therapeutic target to prevent and treat acquired chemoresistance | Q47955849 | ||
| Cisplatin and Pemetrexed Activate AXL and AXL Inhibitor BGB324 Enhances Mesothelioma Cell Death from Chemotherapy. | Q48521717 | ||
| Knockdown of long non-coding RNA HOTAIR inhibits cisplatin resistance of gastric cancer cells through inhibiting the PI3K/Akt and Wnt/β-catenin signaling pathways by up-regulating miR-34a | Q50101496 | ||
| Relevance of copper transporter 1 and organic cation transporters 1-3 for oxaliplatin uptake and drug resistance in colorectal cancer cells. | Q50123707 | ||
| Interactions of cisplatin and the copper transporter CTR1 in human colon cancer cells. | Q50639517 | ||
| Autophagy contributes to the enrichment and survival of colorectal cancer stem cells under oxaliplatin treatment. | Q51000986 | ||
| A HIF-independent, CD133-mediated mechanism of cisplatin resistance in glioblastoma cells. | Q51746123 | ||
| A family of drug transporters: the multidrug resistance-associated proteins. | Q34004952 | ||
| Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary | Q34103978 | ||
| Role of Glutathione in the Regulation of Cisplatin Resistance in Cancer Chemotherapy | Q34159386 | ||
| Recognition of cisplatin adducts by cellular proteins | Q34282236 | ||
| Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals | Q34393336 | ||
| Copper Transporter 2 Regulates Endocytosis and Controls Tumor Growth and Sensitivity to Cisplatin In Vivo | Q34458507 | ||
| DNA strand breaks and apoptosis induced by oxaliplatin in cancer cells | Q34534850 | ||
| Classification Systems of Secondary Active Transporters. | Q34547030 | ||
| Role of multidrug resistance protein 2 (MRP2) in chemoresistance and clinical outcome in oesophageal squamous cell carcinoma | Q34627891 | ||
| Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers | Q34663583 | ||
| Role of endonucleases XPF and XPG in nucleotide excision repair of platinated DNA and cisplatin/oxaliplatin cytotoxicity. | Q34842777 | ||
| An adsorptive transfer technique coupled with brdicka reaction to reveal the importance of metallothionein in chemotherapy with platinum based cytostatics. | Q35002247 | ||
| Current status of the molecular mechanisms of anticancer drug-induced apoptosis. The contribution of molecular-level analysis to cancer chemotherapy | Q35002472 | ||
| Resistance to therapy in BRCA2 mutant cells due to loss of the nucleosome remodeling factor CHD4. | Q35173275 | ||
| Pharmacogenetics of the DNA repair pathways in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy | Q35214307 | ||
| Copper transporters and the cellular pharmacology of the platinum-containing cancer drugs | Q35454498 | ||
| EGCG Enhances Cisplatin Sensitivity by Regulating Expression of the Copper and Cisplatin Influx Transporter CTR1 in Ovary Cancer | Q35558444 | ||
| Mechanism of Cisplatin-Induced Cytotoxicity Is Correlated to Impaired Metabolism Due to Mitochondrial ROS Generation | Q35738714 | ||
| β-elemene sensitizes hepatocellular carcinoma cells to oxaliplatin by preventing oxaliplatin-induced degradation of copper transporter 1. | Q35921211 | ||
| Recognition and processing of cisplatin- and oxaliplatin-DNA adducts | Q35988488 | ||
| Heparanase Enhances Tumor Growth and Chemoresistance by Promoting Autophagy | Q36070533 | ||
| HMGB1-mediated autophagy modulates sensitivity of colorectal cancer cells to oxaliplatin via MEK/ERK signaling pathway | Q36212999 | ||
| JWA reverses cisplatin resistance via the CK2-XRCC1 pathway in human gastric cancer cells | Q36291991 | ||
| miR-634 restores drug sensitivity in resistant ovarian cancer cells by targeting the Ras-MAPK pathway. | Q36293209 | ||
| Role of mismatch repair proteins in the processing of cisplatin interstrand cross-links | Q36296744 | ||
| CITED2 silencing sensitizes cancer cells to cisplatin by inhibiting p53 trans-activation and chromatin relaxation on the ERCC1 DNA repair gene | Q36370912 | ||
| 'BRCAness' and its implications for platinum action in gynecologic cancer | Q36380704 | ||
| Molecular mechanisms of mammalian global genome nucleotide excision repair. | Q36389623 | ||
| miRNA-378 reverses chemoresistance to cisplatin in lung adenocarcinoma cells by targeting secreted clusterin | Q36499755 | ||
| Suppression of Jab1/CSN5 induces radio- and chemo-sensitivity in nasopharyngeal carcinoma through changes to the DNA damage and repair pathways | Q36592296 | ||
| Enhanced repair of DNA interstrand crosslinking in ovarian cancer cells from patients following treatment with platinum-based chemotherapy | Q36611274 | ||
| Overcoming cisplatin resistance of ovarian cancer cells by targeting HIF-1-regulated cancer metabolism | Q36626694 | ||
| The CXXC motifs in the metal binding domains are required for ATP7B to mediate resistance to cisplatin | Q36650582 | ||
| Autophagic control of cell 'stemness'. | Q36685927 | ||
| A phosphotyrosine switch regulates organic cation transporters | Q36704820 | ||
| Tumor microenvironment: the role of the tumor stroma in cancer | Q36709404 | ||
| Protein turnover via autophagy: implications for metabolism | Q36740463 | ||
| Direct cellular responses to platinum-induced DNA damage | Q36800400 | ||
| Mitochondria and reactive oxygen species in renal cancer. | Q36804989 | ||
| The role of ubiquitination in the direct mitochondrial death program of p53. | Q36881193 | ||
| Overcoming platinum resistance through the use of a copper-lowering agent | Q36886892 | ||
| Effector T Cells Abrogate Stroma-Mediated Chemoresistance in Ovarian Cancer | Q36922131 | ||
| The role of cellular accumulation in determining sensitivity to platinum-based chemotherapy | Q36971805 | ||
| Enhanceosomes as integrators of hypoxia inducible factor (HIF) and other transcription factors in the hypoxic transcriptional response. | Q36980048 | ||
| Cathepsin Protease Controls Copper and Cisplatin Accumulation via Cleavage of the Ctr1 Metal-binding Ectodomain. | Q37065664 | ||
| Impaired glutathione synthesis in neurodegeneration | Q37291406 | ||
| Role for DUSP1 (dual-specificity protein phosphatase 1) in the regulation of autophagy | Q37365307 | ||
| Replacement of cisplatin with nedaplatin in a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma | Q37376917 | ||
| Cancer-associated fibroblasts treated with cisplatin facilitates chemoresistance of lung adenocarcinoma through IL-11/IL-11R/STAT3 signaling pathway | Q37476178 | ||
| MiR-99a and MiR-491 Regulate Cisplatin Resistance in Human Gastric Cancer Cells by Targeting CAPNS1. | Q37513892 | ||
| Prognostic significance of hypoxia-inducible factor-1alpha, TWIST1 and Snail expression in resectable non-small cell lung cancer | Q37602926 | ||
| Chk1/2 inhibition overcomes the cisplatin resistance of head and neck cancer cells secondary to the loss of functional p53. | Q37638784 | ||
| Reduced expression of miRNA-27a modulates cisplatin resistance in bladder cancer by targeting the cystine/glutamate exchanger SLC7A11. | Q37682756 | ||
| Ammonium tetrathiomolybdate treatment targets the copper transporter ATP7A and enhances sensitivity of breast cancer to cisplatin | Q37686235 | ||
| The relationship between cisplatin-induced reactive oxygen species, glutathione, and BCL-2 and resistance to cisplatin | Q37693895 | ||
| Copper transporter 2 regulates intracellular copper and sensitivity to cisplatin | Q37696191 | ||
| Targeting the prodeath and prosurvival functions of autophagy as novel therapeutic strategies in cancer | Q37707832 | ||
| Let-7e sensitizes epithelial ovarian cancer to cisplatin through repressing DNA double strand break repair | Q37736667 | ||
| Human copper transporters: mechanism, role in human diseases and therapeutic potential | Q37747071 | ||
| Overexpression of long non-coding RNA PVT1 in gastric cancer cells promotes the development of multidrug resistance | Q38877475 | ||
| MEK Inhibition Overcomes Cisplatin Resistance Conferred by SOS/MAPK Pathway Activation in Squamous Cell Carcinoma. | Q38879231 | ||
| miR-148b reverses cisplatin-resistance in non-small cell cancer cells via negatively regulating DNA (cytosine-5)-methyltransferase 1(DNMT1) expression | Q38880588 | ||
| MiR-205 and miR-218 expression is associated with carboplatin chemoresistance and regulation of apoptosis via Mcl-1 and Survivin in lung cancer cells | Q38881755 | ||
| The anti-malarial chloroquine suppresses proliferation and overcomes cisplatin resistance of endometrial cancer cells via autophagy inhibition. | Q38890954 | ||
| The overexpression and nuclear translocation of Trx-1 during hypoxia confers on HepG2 cells resistance to DDP, and GL-V9 reverses the resistance by suppressing the Trx-1/Ref-1 axis | Q38912419 | ||
| Pseudohypoxia induced by miR-126 deactivation promotes migration and therapeutic resistance in renal cell carcinoma. | Q38930757 | ||
| Chromatin status of apoptosis genes correlates with sensitivity to chemo-, immune- and radiation therapy in colorectal cancer cell lines | Q38949945 | ||
| Induction of autophagy counteracts the anticancer effect of cisplatin in human esophageal cancer cells with acquired drug resistance | Q38955141 | ||
| miR-let-7f-1 regulates SPARC mediated cisplatin resistance in medulloblastoma cells | Q38976273 | ||
| Epithelial-mesenchymal status renders differential responses to cisplatin in ovarian cancer. | Q38992054 | ||
| Zinc chelation: a metallothionein 2A's mechanism of action involved in osteosarcoma cell death and chemotherapy resistance. | Q39070928 | ||
| miR-495 enhances the sensitivity of non-small cell lung cancer cells to platinum by modulation of copper-transporting P-type adenosine triphosphatase A (ATP7A). | Q39095757 | ||
| Hypoxia inducible factor-1α induces chemoresistance phenotype in non-Hodgkin lymphoma cell line via up-regulation of Bcl-xL. | Q39271109 | ||
| The African-specific S47 polymorphism of p53 alters chemosensitivity | Q39532523 | ||
| Epigenetic activation of the drug transporter OCT2 sensitizes renal cell carcinoma to oxaliplatin | Q39578254 | ||
| Downregulation of XPF-ERCC1 enhances cisplatin efficacy in cancer cells. | Q39711077 | ||
| The internalization and degradation of human copper transporter 1 following cisplatin exposure | Q39774950 | ||
| Silencing MRP4 by small interfering RNA reverses acquired DDP resistance of gastric cancer cell | Q39780172 | ||
| Copper transporters and chaperones CTR1, CTR2, ATOX1, and CCS as determinants of cisplatin sensitivity | Q39785045 | ||
| The ERCC1/XPF endonuclease is required for completion of homologous recombination at DNA replication forks stalled by inter-strand cross-links | Q39807128 | ||
| Oxidative stress is inherent in prostate cancer cells and is required for aggressive phenotype | Q40002565 | ||
| Transport of cisplatin by the copper efflux transporter ATP7B. | Q40058081 | ||
| Differential contribution of organic cation transporters, OCT2 and MATE1, in platinum agent-induced nephrotoxicity | Q40117154 | ||
| ABCC2 (MRP2, cMOAT) can be localized in the nuclear membrane of ovarian carcinomas and correlates with resistance to cisplatin and clinical outcome | Q40200907 | ||
| Augmentation of cisplatin sensitivity in cisplatin-resistant human bladder cancer cells by modulating glutathione concentrations and glutathione-related enzyme activities | Q40433330 | ||
| Cellular accumulation of the anticancer agent cisplatin: a review | Q40917698 | ||
| Oxaliplatin-Based Chemotherapy in Advanced Neuroendocrine Tumors: Clinical Outcomes and Preliminary Correlation with Biological Factors | Q40963478 | ||
| Sensitivity of testis tumour cells to chemotherapeutic drugs: role of detoxifying pathways | Q41194881 | ||
| Cytoplasmic fragment of CD147 generated by regulated intramembrane proteolysis contributes to HCC by promoting autophagy | Q41335207 | ||
| ZBTB7A Enhances Osteosarcoma Chemoresistance by Transcriptionally Repressing lncRNALINC00473-IL24 Activity | Q41667208 | ||
| Downregulation of YEATS4 by miR-218 sensitizes colorectal cancer cells to L-OHP-induced cell apoptosis by inhibiting cytoprotective autophagy | Q41914079 | ||
| Carboplatin and oxaliplatin in sequenced combination with bortezomib in ovarian tumour models | Q41978951 | ||
| miR-34a mediates oxaliplatin resistance of colorectal cancer cells by inhibiting macroautophagy via transforming growth factor-β/Smad4 pathway | Q42316098 | ||
| GFRA1 promotes cisplatin-induced chemoresistance in osteosarcoma by inducing autophagy | Q42330104 | ||
| Microenvironmental InterFereNce of metabolism regulates chemosensitivity. | Q42381317 | ||
| CRISPR-Cas9-based target validation for p53-reactivating model compounds. | Q42577802 | ||
| MiR-200c regulates tumor growth and chemosensitivity to cisplatin in osteosarcoma by targeting AKT2 | Q42659697 | ||
| Cisplatin interaction with amino acids cysteine and methionine from gas phase to solutions with constant pH. | Q42966354 | ||
| Modulation of the cellular pharmacology of cisplatin and its analogs by the copper exporters ATP7A and ATP7B. | Q43415914 | ||
| Formation and repair of cisplatin-induced adducts to DNA in cultured normal and repair-deficient human fibroblasts. | Q43484172 | ||
| Role of human copper transporter Ctr1 in the transport of platinum-based antitumor agents in cisplatin-sensitive and cisplatin-resistant cells | Q45213244 | ||
| Increased levels of copper efflux transporter ATP7B are associated with poor outcome in colorectal cancer patients receiving oxaliplatin-based chemotherapy. | Q46083726 | ||
| Glutathione reductase mediates drug resistance in glioblastoma cells by regulating redox homeostasis. | Q46268407 | ||
| Xc- inhibitor sulfasalazine sensitizes colorectal cancer to cisplatin by a GSH-dependent mechanism | Q46687271 | ||
| Lysine-specific demethylase KDM3A regulates ovarian cancer stemness and chemoresistance | Q47135415 | ||
| LncRNA UCA1 promotes proliferation and cisplatin resistance of oral squamous cell carcinoma by sunppressing miR-184 expression | Q47159465 | ||
| miR-181 regulates cisplatin-resistant non-small cell lung cancer via downregulation of autophagy through the PTEN/PI3K/AKT pathway. | Q52683993 | ||
| Downregulation of HIF-2α Reverse the Chemotherapy Resistance of Lung Adenocarcinoma A549 Cells to Cisplatin. | Q52731051 | ||
| LncRNA XIST promotes human lung adenocarcinoma cells to cisplatin resistance via let-7i/BAG-1 axis. | Q52753259 | ||
| Histone Methyltransferase G9a Drives Chemotherapy Resistance by Regulating the Glutamate-Cysteine Ligase Catalytic Subunit in Head and Neck Squamous Cell Carcinoma. | Q52895624 | ||
| Reversal of cisplatin resistance by microRNA-139-5p-independent RNF2 downregulation and MAPK inhibition in ovarian cancer. | Q53689012 | ||
| Competitive reactions among glutathione, cisplatin and copper-phenanthroline complexes. | Q53740004 | ||
| Kidney cancer: OCT2 demethylation cracks open oxaliplatin resistance. | Q53774743 | ||
| KLF5 mediates vascular remodeling via HIF-1α in hypoxic pulmonary hypertension. | Q53804088 | ||
| Inhibition of cisplatin-resistance by RNA interference targeting metallothionein using reducible oligo-peptoplex. | Q53830353 | ||
| ATP-dependent transport of glutathione S-conjugates by the multidrug resistance-associated protein. | Q54195051 | ||
| Phase II study of adjuvant chemotherapy with paclitaxel and nedaplatin for uterine cervical cancer with lymph node metastasis. | Q54249091 | ||
| Structure, Recognition, and Processing of Cisplatin-DNA Adducts. | Q55035583 | ||
| Knockdown of KLF5 suppresses hypoxia-induced resistance to cisplatin in NSCLC cells by regulating HIF-1α-dependent glycolysis through inactivation of the PI3K/Akt/mTOR pathway. | Q55280857 | ||
| MicroRNA-125a-5p enhances the sensitivity of esophageal squamous cell carcinoma cells to cisplatin by suppressing the activation of the STAT3 signaling pathway. | Q55419057 | ||
| miR-874 regulates multiple-drug resistance in gastric cancer by targeting ATG16L1 | Q57476082 | ||
| Activated Integrated Stress Response Induced by Salubrinal Promotes Cisplatin Resistance in Human Gastric Cancer Cells via Enhanced xCT Expression and Glutathione Biosynthesis | Q58103531 | ||
| LncRNA MALAT1 potentiates autophagy‑associated cisplatin resistance by regulating the microRNA‑30b/autophagy‑related gene 5 axis in gastric cancer | Q58543570 | ||
| Knockdown of galectin-1 facilitated cisplatin sensitivity by inhibiting autophagy in neuroblastoma cells | Q58570966 | ||
| miR‑34a regulates the chemosensitivity of retinoblastoma cells via modulation of MAGE‑A/p53 signaling | Q58584892 | ||
| LncRNA BLACAT1 is involved in chemoresistance of non‑small cell lung cancer cells by regulating autophagy | Q58584902 | ||
| A Whole-genome CRISPR Screen Identifies a Role of MSH2 in Cisplatin-mediated Cell Death in Muscle-invasive Bladder Cancer | Q58595174 | ||
| Induction of p53 Phosphorylation at Serine 20 by Resveratrol Is Required to Activate p53 Target Genes, Restoring Apoptosis in MCF-7 Cells Resistant to Cisplatin | Q58710535 | ||
| Comparison of efficacy and toxicity between nedaplatin and cisplatin in treating malignant pleural effusion | Q58762812 | ||
| LncRNA HOXA11-AS drives cisplatin resistance of human LUAD cells via modulating miR-454-3p/Stat3 | Q58769775 | ||
| Oxaliplatin-induced damage of cellular DNA | Q60641674 | ||
| Tetrathiomolybdate induces dimerization of the metal-binding domain of ATPase and inhibits platination of the protein | Q60909406 | ||
| Exosomal miR-196a derived from cancer-associated fibroblasts confers cisplatin resistance in head and neck cancer through targeting CDKN1B and ING5 | Q61448904 | ||
| HIF-1-Dependent Reprogramming of Glucose Metabolic Pathway of Cancer Cells and Its Therapeutic Significance | Q61799540 | ||
| BRCA1/2 mutations and expression: Response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer | Q62112707 | ||
| Glutathione-associated cis-diamminedichloroplatinum(II) metabolism and ATP-dependent efflux from leukemia cells. Molecular characterization of glutathione-platinum complex and its biological significance | Q72932284 | ||
| Metallothionein expression correlates with the pathological response of patients with esophageal cancer undergoing preoperative chemoradiation therapy | Q77796057 | ||
| Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin, carboplatin, and oxaliplatin | Q79922423 | ||
| Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family) | Q80128982 | ||
| Expression of hypoxia-inducible factor 1alpha, hypoxia-inducible factor 2alpha, and von Hippel-Lindau protein in epithelial ovarian neoplasms and allelic loss of von Hippel-Lindau gene: nuclear expression of hypoxia-inducible factor 1alpha is an ind | Q80445905 | ||
| Immunohistochemical expression of MRP2 and clinical resistance to platinum-based chemotherapy in small cell lung cancer | Q80536626 | ||
| Low ERCC1 expression is associated with prolonged survival in patients with bladder cancer receiving platinum-based neoadjuvant chemotherapy | Q84730836 | ||
| Serum metallothionein in patients with testicular cancer | Q86786642 | ||
| Glutathione depletion sensitizes cisplatin- and temozolomide-resistant glioma cells in vitro and in vivo | Q87126485 | ||
| MircroRNA-139 sensitizes ovarian cancer cell to cisplatin-based chemotherapy through regulation of ATP7A/B | Q88208744 | ||
| DUOXA1-mediated ROS production promotes cisplatin resistance by activating ATR-Chk1 pathway in ovarian cancer | Q88500255 | ||
| Gambogic Acid Inhibits Melanoma through Regulation of miR-199a-3p/ZEB1 Signalling | Q89360330 | ||
| ABT737 reverses cisplatin resistance by targeting glucose metabolism of human ovarian cancer cells | Q90277883 | ||
| BRCA Mutation and Its Association With Colorectal Cancer | Q90392429 | ||
| Emerging platinum(iv) prodrugs to combat cisplatin resistance: from isolated cancer cells to tumor microenvironment | Q90999761 | ||
| Profiling of apoptosis- and autophagy-associated molecules in human lung cancer A549 cells in response to cisplatin treatment using stable isotope labeling with amino acids in cell culture | Q91139685 | ||
| miR-137 mediates the functional link between c-Myc and EZH2 that regulates cisplatin resistance in ovarian cancer | Q91239726 | ||
| Inositol-triphosphate 3-kinase B confers cisplatin resistance by regulating NOX4-dependent redox balance | Q91971712 | ||
| Regulation of OCT2 transcriptional repression by histone acetylation in renal cell carcinoma | Q92016223 | ||
| Cisplatin resistance involves a metabolic reprogramming through ROS and PGC-1α in NSCLC which can be overcome by OXPHOS inhibition | Q92422009 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P304 | page(s) | 343 | |
| P577 | publication date | 2020-03-20 | |
| P1433 | published in | Frontiers in Pharmacology | Q2681208 |
| P1476 | title | The Drug-Resistance Mechanisms of Five Platinum-Based Antitumor Agents | |
| P478 | volume | 11 |
Search more.